Phase II evaluation of merbarone in renal cell carcinoma

Keyphrases

• Renal Cell Carcinoma 100%
• Merbarone 100%
• Response Rate 66%
• Dizziness 33%
• Weight Loss 33%
• Diarrhea 33%
• Adverse Drug Reaction 33%
• Hyperglycemia 33%
• Moderate to Severe 33%
• Anemia 33%
• Partial Response 33%
• Hypercalcemia 33%
• Southwest Oncology Group 33%
• Vertigo 33%
• Continuous Infusion 33%
• Treatment-related Mortality 33%
• Dyspnea 33%
• Metastatic Renal Cell Carcinoma (mRCC) 33%
• Nausea-vomiting 33%
• Lethargy 33%
• Advanced Renal Cell Carcinoma 33%
• Granulocytopenia 33%
• Malaise 33%
• Creatinine Increase 33%
• Mixed Response 33%
• Pedal Edema 33%

Medicine and Dentistry

• Clear Cell Renal Cell Carcinoma 100%
• Merbarone 100%
• Oncology 33%
• Hypercalcaemia 33%
• Dizziness 33%
• Diarrhea 33%
• Anemia 33%
• Creatinine 33%
• Hyperglycemia 33%
• Adverse Drug Reaction 33%
• Vertigo 33%
• Continuous Infusion 33%
• Dyspnea 33%
• Kidney Metastasis 33%
• Nausea 33%
• Malaise 33%
• Granulocytopenia 33%
• Foot Edema 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Renal Cell Carcinoma 100%
• Merbarone 100%
• Hypercalcaemia 33%
• Anemia 33%
• Adverse Drug Reaction 33%
• Diarrhea 33%
• Hyperglycemia 33%
• Dizziness 33%
• Nausea 33%
• Dyspnea 33%
• Kidney Metastasis 33%
• Creatinine 33%
• Granulocytopenia 33%
• Malaise 33%
• Foot Edema 33%
• Vertigo 33%